NR565 ADVANCED PHARMACOLOGY FINAL EXAM
2026/2027 | Complete Review | Chamberlain | Pass
Guaranteed - A+ Graded
SECTION 1: Pharmacokinetics & Pharmacodynamics (Q1-Q16)
Q1: Which pharmacokinetic parameter is defined as the proportion of an administered
drug that reaches systemic circulation in an unchanged form?
A. Bioavailability [CORRECT]
B. Therapeutic index
C. Half-life
D. Clearance
Correct Answer: A
Rationale: Bioavailability (F) specifically measures the fraction of administered drug that
enters systemic circulation unchanged. The therapeutic index (B) is a safety ratio,
half-life (C) is elimination time, and clearance (D) is the volume of blood cleared of drug
per unit time.
Q2: A patient taking warfarin is prescribed trimethoprim-sulfamethoxazole for a urinary
tract infection. The nurse practitioner recognizes that this combination increases
bleeding risk primarily through which mechanism?
A. Trimethoprim-sulfamethoxazole inhibits CYP2C9, reducing warfarin metabolism
[CORRECT]
B. Trimethoprim-sulfamethoxazole induces CYP3A4, increasing warfarin clearance
C. The combination increases warfarin absorption from the GI tract
D. Sulfamethoxazole displaces warfarin from albumin, increasing its volume of
distribution
,Correct Answer: A
Rationale: Sulfamethoxazole is a known CYP2C9 inhibitor, and warfarin (especially
S-warfarin) is metabolized primarily by CYP2C9; inhibition increases warfarin plasma
levels and bleeding risk. Option B incorrectly states induction; C is incorrect because
absorption is not significantly altered; D describes a possible minor mechanism but not
the primary interaction.
Q3: A 70-year-old patient with renal impairment is prescribed gentamicin. The desired
peak concentration is 6 mcg/mL and the volume of distribution is 0.25 L/kg. The patient
weighs 80 kg. Using the formula Dose = Cp(desired) × Vd, what is the required dose in
milligrams?
A. 100 mg
B. 120 mg [CORRECT]
C. 150 mg
D. 180 mg
Correct Answer: B
Rationale: Vd = 0.25 L/kg × 80 kg = 20 L. Dose = 6 mcg/mL × 20 L = 6 mg/L × 20 L = 120
mg. Option A miscalculates Vd; C and D result from arithmetic errors or incorrect unit
conversions.
Q4: A highly protein-bound drug (98%) is prescribed to a patient with hypoalbuminemia.
The nurse practitioner anticipates which pharmacokinetic change?
A. Increased free drug concentration and potentially enhanced pharmacologic effect or
toxicity [CORRECT]
B. Decreased free drug concentration due to reduced binding sites
C. Increased drug half-life due to greater protein binding
D. Decreased volume of distribution
Correct Answer: A
,Rationale: When albumin is low, less drug is bound to protein, increasing the free
(active) fraction available to exert effects and potentially causing toxicity. Option B is
physiologically opposite; C is incorrect because reduced protein binding typically
increases clearance; D is incorrect because low protein generally increases Vd.
Q5: Which organ is primarily responsible for the first-pass effect, significantly reducing
the bioavailability of orally administered drugs such as nitroglycerin?
A. Liver [CORRECT]
B. Kidney
C. Lung
D. Spleen
Correct Answer: A
Rationale: The liver is the primary site of first-pass metabolism, where drugs absorbed
from the GI tract pass through the hepatic portal circulation before entering systemic
circulation. Options B, C, and D are not the primary organs for first-pass drug
metabolism.
Q6: A patient receiving digoxin develops nausea, vomiting, and a new-onset arrhythmia.
The serum digoxin level is 3.2 ng/mL. The nurse practitioner recognizes these findings
as consistent with which adverse effect pattern?
A. Digoxin toxicity [CORRECT]
B. Digoxin therapeutic effect
C. Hypokalemia unrelated to digoxin
D. Digoxin allergic reaction
Correct Answer: A
Rationale: Digoxin has a narrow therapeutic index (0.5-0.9 ng/mL therapeutic; >2 ng/mL
toxic), and levels of 3.2 ng/mL produce characteristic GI and cardiac toxicity symptoms.
Option B is incorrect because these are toxic, not therapeutic, effects; C may contribute
, but is not the primary pattern; D is incorrect because these are dose-related toxicities,
not allergic reactions.
Q7: A patient begins taking phenytoin for seizure control. The nurse practitioner
explains that steady-state concentration will be reached in approximately how many
days given phenytoin's half-life of 22 hours?
A. 1-2 days
B. 3-4 days
C. 4-5 days [CORRECT]
D. 7-8 days
Correct Answer: C
Rationale: Steady state is reached in approximately 4-5 half-lives; with a 22-hour
half-life, this equals 88-110 hours or roughly 4-5 days. Option A represents 1-2 half-lives;
B represents ~2-3 half-lives; D exceeds the standard 4-5 half-life rule.
Q8: A drug that binds to a receptor and produces a response equal to the endogenous
ligand is best classified as which type of pharmacologic agent?
A. Full agonist [CORRECT]
B. Partial agonist
C. Competitive antagonist
D. Inverse agonist
Correct Answer: A
Rationale: A full agonist produces a maximal response equivalent to the endogenous
ligand when occupying the same receptor. A partial agonist (B) produces submaximal
response; a competitive antagonist (C) blocks the receptor without activating it; an
inverse agonist (D) produces an opposite effect to the endogenous ligand.
2026/2027 | Complete Review | Chamberlain | Pass
Guaranteed - A+ Graded
SECTION 1: Pharmacokinetics & Pharmacodynamics (Q1-Q16)
Q1: Which pharmacokinetic parameter is defined as the proportion of an administered
drug that reaches systemic circulation in an unchanged form?
A. Bioavailability [CORRECT]
B. Therapeutic index
C. Half-life
D. Clearance
Correct Answer: A
Rationale: Bioavailability (F) specifically measures the fraction of administered drug that
enters systemic circulation unchanged. The therapeutic index (B) is a safety ratio,
half-life (C) is elimination time, and clearance (D) is the volume of blood cleared of drug
per unit time.
Q2: A patient taking warfarin is prescribed trimethoprim-sulfamethoxazole for a urinary
tract infection. The nurse practitioner recognizes that this combination increases
bleeding risk primarily through which mechanism?
A. Trimethoprim-sulfamethoxazole inhibits CYP2C9, reducing warfarin metabolism
[CORRECT]
B. Trimethoprim-sulfamethoxazole induces CYP3A4, increasing warfarin clearance
C. The combination increases warfarin absorption from the GI tract
D. Sulfamethoxazole displaces warfarin from albumin, increasing its volume of
distribution
,Correct Answer: A
Rationale: Sulfamethoxazole is a known CYP2C9 inhibitor, and warfarin (especially
S-warfarin) is metabolized primarily by CYP2C9; inhibition increases warfarin plasma
levels and bleeding risk. Option B incorrectly states induction; C is incorrect because
absorption is not significantly altered; D describes a possible minor mechanism but not
the primary interaction.
Q3: A 70-year-old patient with renal impairment is prescribed gentamicin. The desired
peak concentration is 6 mcg/mL and the volume of distribution is 0.25 L/kg. The patient
weighs 80 kg. Using the formula Dose = Cp(desired) × Vd, what is the required dose in
milligrams?
A. 100 mg
B. 120 mg [CORRECT]
C. 150 mg
D. 180 mg
Correct Answer: B
Rationale: Vd = 0.25 L/kg × 80 kg = 20 L. Dose = 6 mcg/mL × 20 L = 6 mg/L × 20 L = 120
mg. Option A miscalculates Vd; C and D result from arithmetic errors or incorrect unit
conversions.
Q4: A highly protein-bound drug (98%) is prescribed to a patient with hypoalbuminemia.
The nurse practitioner anticipates which pharmacokinetic change?
A. Increased free drug concentration and potentially enhanced pharmacologic effect or
toxicity [CORRECT]
B. Decreased free drug concentration due to reduced binding sites
C. Increased drug half-life due to greater protein binding
D. Decreased volume of distribution
Correct Answer: A
,Rationale: When albumin is low, less drug is bound to protein, increasing the free
(active) fraction available to exert effects and potentially causing toxicity. Option B is
physiologically opposite; C is incorrect because reduced protein binding typically
increases clearance; D is incorrect because low protein generally increases Vd.
Q5: Which organ is primarily responsible for the first-pass effect, significantly reducing
the bioavailability of orally administered drugs such as nitroglycerin?
A. Liver [CORRECT]
B. Kidney
C. Lung
D. Spleen
Correct Answer: A
Rationale: The liver is the primary site of first-pass metabolism, where drugs absorbed
from the GI tract pass through the hepatic portal circulation before entering systemic
circulation. Options B, C, and D are not the primary organs for first-pass drug
metabolism.
Q6: A patient receiving digoxin develops nausea, vomiting, and a new-onset arrhythmia.
The serum digoxin level is 3.2 ng/mL. The nurse practitioner recognizes these findings
as consistent with which adverse effect pattern?
A. Digoxin toxicity [CORRECT]
B. Digoxin therapeutic effect
C. Hypokalemia unrelated to digoxin
D. Digoxin allergic reaction
Correct Answer: A
Rationale: Digoxin has a narrow therapeutic index (0.5-0.9 ng/mL therapeutic; >2 ng/mL
toxic), and levels of 3.2 ng/mL produce characteristic GI and cardiac toxicity symptoms.
Option B is incorrect because these are toxic, not therapeutic, effects; C may contribute
, but is not the primary pattern; D is incorrect because these are dose-related toxicities,
not allergic reactions.
Q7: A patient begins taking phenytoin for seizure control. The nurse practitioner
explains that steady-state concentration will be reached in approximately how many
days given phenytoin's half-life of 22 hours?
A. 1-2 days
B. 3-4 days
C. 4-5 days [CORRECT]
D. 7-8 days
Correct Answer: C
Rationale: Steady state is reached in approximately 4-5 half-lives; with a 22-hour
half-life, this equals 88-110 hours or roughly 4-5 days. Option A represents 1-2 half-lives;
B represents ~2-3 half-lives; D exceeds the standard 4-5 half-life rule.
Q8: A drug that binds to a receptor and produces a response equal to the endogenous
ligand is best classified as which type of pharmacologic agent?
A. Full agonist [CORRECT]
B. Partial agonist
C. Competitive antagonist
D. Inverse agonist
Correct Answer: A
Rationale: A full agonist produces a maximal response equivalent to the endogenous
ligand when occupying the same receptor. A partial agonist (B) produces submaximal
response; a competitive antagonist (C) blocks the receptor without activating it; an
inverse agonist (D) produces an opposite effect to the endogenous ligand.
